We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression. We have identified drug targets to treat the root causes of facioscapulohumeral muscular dystrophy (FSHD) and certain hemoglobinopathies, namely sickle cell disease (SCD) and b-thalassemia. Source
No articles found.
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Systec & Solutions GmbH, with headquarters in Karlsruhe (Germany), is a specialize...
Systec & Solutions GmbH, with headquarters in K...
Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...
Viveve, Inc., the wholly owned subsidiary of Vi...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Join the National Investor Network and get the latest information with your interests in mind.